|
Alcon, the global leader in eye care has launched the Clareon Family of intraocular lenses (IOLs) in India. Clareon delivers consistent visual outcomes and exceptional clarity that lasts. Its IOL material has among the lowest levels of haze and subsurface nanoglistenings (SSNGs), compared to leading competitor IOLs.
The Clareon platform is available in India in two PCIOL technologies: These are the PanOptix, which delivers exceptional clarity and offers spectacle independence across all distances with a patient satisfaction rate of 99.2%.
PanOptix Trifocal IOL, is implanted over 2.2 million times, making it the most widely implanted trifocal IOL in the world. The Clareon Vivity with wave front-shaping X- WAVE technology, offers clinically proven exceptionally low rate of visual disturbances and unsurpassed clarity. The Vivity IOL, designed to extend vision and simplify the presbyopia-correcting experience for surgeons and patients while delivering monofocal-like certainty.
“We offer the full range of our latest IOL technology to patients in India. We are consistently pushing the boundaries to deliver transformational innovation to cataract surgeons and their patients,” said Amar Vyas, country head of Alcon India.
“Clareon builds on Alcon’s long legacy of IOL innovation and is the result of robust R&D efforts at every level—inventive material science, advanced manufacturing techniques and novel delivery systems. Our most advanced platform to date, Clareon delivers exceptional, long-lasting clarity,” he added.
The IOLs offer sharp, crisp vision with a proprietary edge designed to help reduce glare and posterior capsular opacification. The lens’ unique and proven Stableforce Haptics provide superior axial and rotational stability. Clareon IOLs have been extensively researched, with inclusions in 30 published studies worldwide.
More than 28 million cataract surgeries are performed each year in the world. With the aging population and increased life expectancies, these surgeries are expected to increase 3-4% per year for the next 30 years, leading to an estimated 60 million global cataract surgeries annually by 2045.
|